News

CMC ICOS Biologics and Implicit Bioscience Ltd Announce IC14 Antibody Manufacturing Agreement and Patent License

BOTHELL, Wash. and BRISBANE, Australia - May 8, 2009 Implicit Bioscience Ltd and CMC ICOS Biologics today announced the execution of a manufacturing contract to support the next stage of development and commercialization of IC14,...

UW Bothell and CMC ICOS Announce Public/Private Agreement

BOTHELL, Wash. – The University of Washington Bothell and CMC ICOS Biologics, a company dedicated to contract development and manufacturing for the biotechnology sector, announced a public/private agreement today.

The agreement...

CMC Biologics A/S announced today the appointment of Dr Bernard Chan as Chief Business Officer

Copenhagen, Denmark; March 2, 2009 CMC Biologics A/S announced today the appointment of Dr Bernard Chan, Chief Business Officer. Dr Chan was previously Director of Biologicals Manufacturing Development for UCB (and formerly...

CMC has entered into an agreement with Symphogen A/S for process development and cGMP manufacture.

COPENHAGEN, DENMARK; August 05, 2008CMC Biologics A/S announced today that it has entered into an agreement with Symphogen A/S for process development and cGMP manufacture of an undisclosed polyclonal antibody product candidate...

Acorda Therapeutics, Inc. Signs GGF2 Manufacturing Agreement with CMC ICOS Biologics, Inc.

HAWTHORNE, NY and COPENHAGEN, DENMARK – April 9, 2008Acorda Therapeutics, Inc. (NASDAQ: ACOR) and CMC ICOS Biologics. Inc. today announced that Acorda has selected CMC ICOS as the contract manufacturer for GGF2, the lead molecule...